Viral Hemorrhagic Fever Market: Overview

Viral hemorrhagic fever is referred to as severe multisystem (multiple organs) syndrome in our body that is affected by certain viruses. Viral hemorrhagic fever can be described as a group of illness caused by four families of RNA viruses namely arenaviruses, filoviruses, bunyaviruses and flaviviruses. Due to hemorrhagic fever, the overall vascular system in our body gets damaged and the body loses its ability to regulate. Hemorrhagic fever is rarely life threatening but sometimes it leads to emergency medical conditions. The Centers for Disease Control and Prevention (CDC) has stated that the natural reservoir (host) for the causative organism of hemorrhagic fever is an animal or insect, but humans are infected when they come into contact with infected hosts.

It has also stated that most of the viruses associated with viral hemorrhagic fever are considered as zoonotic (animal host). Few animals which act as a host for hemorrhagic fever includes rat, cotton rat, deer mouse, house mouse, and other field rodents. Few examples of viral hemorrhagic fever include ebola, marburg, dengue, lassa and yellow fever. Possible signs and symptoms of viral hemorrhagic fever include fatigue, muscle pain, bone or joint aches, high fever and dizziness. Other signs and symptoms considered as life threatening includes shock, nervous system malfunctions, coma, delirium, kidney failure and liver failure.

Risk factor for viral hemorrhagic fever includes slaughtering infected animals, working with the sick, sharing needles to use intravenous drugs, having unprotected sex and working outdoors or in rat-infected buildings. Possible complication associated with viral hemorrhagic fever includes brain damage, heart failure, kidney damage and malfunctioning of the liver. Presently, there is no specific diagnosis and proper treatment option is available in the market to treat viral hemorrhagic fever.

Get Free PDF Brochure for more Professional and Technical industry insights:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13619

Viral Hemorrhagic Fever Market: Growth Enablers

Increasing unhygienic lifestyle among population is considered as a major market driving factor for the global viral hemorrhagic fever treatment market because animal that resides close contact with human are act as host for the viruses. Moreover, increasing awareness among people about hemorrhagic fever would further accentuate the market growth in few of the developed nations in the world.

Since, currently no treatment option has been made available in the market for hemorrhagic fever, the virus has the potential to being utilize as bio-warfare. The above mentioned factor is considered as a significant ethical issue worldwide. However, the low awareness about viral hemorrhagic fever in a few of the developing nations is considered as a factor that might restrict its demand in the global viral hemorrhagic fever treatment market.

Viral Hemorrhagic Fever Market: Region-wise Insight

North America and Europe dominate the global market for viral hemorrhagic fever treatment due to increasing awareness among people and high prevalence rate of viral hemorrhagic fever in these regions. Moreover, initiatives taken by the federal government also help the market growth in North American and European regions.

Asia-Pacific is considered as an untapped market due to lack of proper healthcare facilities in few Asian countries. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure (healthcare cost, healthcare facility and healthcare budget). Rest of the world (RoW) holds fourth position in the global viral hemorrhagic fever treatment market due to poor economic and health condition in most of the African countries.